NICE Recommends Sovaldi
BMI View : NICE's preliminary recommendation of Sovaldi for the most common types of hepatitis C has strengthened Gilead's case for premium pricing. Having convinced the most stringent regulator in Europe, the company can expect further reimbursement approvals from health technology assessors in Europe on favourable terms. This recommendation highlights the need for drugmakers to effectively demonstrate improvements in outcomes in order to charge premium prices.
The UK's cost-effectiveness watchdog, the National Institute for Health and Care Excellence (NICE), has granted provisional approval for Gilead Sciences' Sovaldi (sofosbuvir), paving the way for the drug's procurement by the NHS and inclusion onto the British National Formulary. In return for a pricing concession (USD57,000 versus a price of USD84,000 in the US), NICE stated that Sovaldi met the criteria of 'clinical and cost effectiveness', criteria that had earlier prompted the rejection of Roche's Kadcyla (transtuzumab emtansine) for treating breast cancer patients.
The most important details to emerge from NICE's draft guidance were:
Share Price Reaches All Time Highs Gilead Share Price, 2009-2014